Target Validation Information | |||||
---|---|---|---|---|---|
Target ID | T96788 | ||||
Target Name | mRNA of HER2 | ||||
Target Type | Clinical Trial |
||||
Drug Potency against Target | BMS-536924 | Drug Info | IC50 = 17100 nM | [1] | |
4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole | Drug Info | IC50 = 13500 nM | [2] | ||
4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole | Drug Info | IC50 = 11000 nM | [2] | ||
4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole | Drug Info | IC50 = 6600 nM | [2] | ||
AG-213 | Drug Info | IC50 = 5700 nM | [3] | ||
(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine | Drug Info | IC50 = 1300 nM | [4] | ||
4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide | Drug Info | IC50 = 1880 nM | [5] | ||
CL-387785 | Drug Info | IC50 = 17 nM | [6] | ||
17-allylamino-17-desmethoxy-geldanamycin | Drug Info | IC50 = 31 nM | [7] | ||
HKI-272 | Drug Info | IC50 = 59 nM | [8] | ||
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide | Drug Info | IC50 = 2.2 nM | [9] | ||
4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole | Drug Info | IC50 = 7900 nM | [2] | ||
PD-168393 | Drug Info | IC50 = 5.7 nM | [9] | ||
References | |||||
REF 1 | J Med Chem. 2005 Sep 8;48(18):5639-43.Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. | ||||
REF 2 | Bioorg Med Chem. 2007 Feb 1;15(3):1533-8. Epub 2006 Dec 15.Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. | ||||
REF 3 | Eur J Med Chem. 2008 Jul;43(7):1478-88. Epub 2007 Sep 29.Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. | ||||
REF 4 | Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. | ||||
REF 5 | Bioorg Med Chem. 2010 Jan 15;18(2):880-6. Epub 2009 Nov 22.Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumoragents. | ||||
REF 6 | J Med Chem. 2006 Feb 23;49(4):1475-85.Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. | ||||
REF 7 | Bioorg Med Chem. 2009 Mar 15;17(6):2225-35. Epub 2008 Nov 6.Discovery and development of heat shock protein 90 inhibitors. | ||||
REF 8 | Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41. Epub 2007 Dec 6.Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. | ||||
REF 9 | J Med Chem. 1999 May 20;42(10):1803-15.Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding siteof the epidermal growth factor receptor. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.